Cardiol Therapeutics Inc Class A CRDL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CAD 2.84
- Day Range
- CAD 2.66–2.88
- 52-Week Range
- CAD 0.74–2.94
- Bid/Ask
- CAD 2.74 / CAD 2.77
- Market Cap
- CAD 187.06 Mil
- Volume/Avg
- 130,519 / 153,581
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.cardiolrx.com
Comparables
Valuation
|
Metric
|
CRDL
|
TGTX
|
ARQT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 20.04 | — |
Price/Book Value | 7.51 | 14.98 | 9.65 |
Price/Sales | — | 10.09 | 10.28 |
Price/Cash Flow | — | 44.29 | — |
Price/Earnings
CRDL
TGTX
ARQT
Financial Strength
|
Metric
|
CRDL
|
TGTX
|
ARQT
|
|---|---|---|---|
Quick Ratio | 4.24 | 5.00 | 6.38 |
Current Ratio | 4.36 | 5.92 | 7.08 |
Interest Coverage | — | 2.04 | −7.72 |
Quick Ratio
CRDL
TGTX
ARQT
Profitability
|
Metric
|
CRDL
|
TGTX
|
ARQT
|
|---|---|---|---|
Return on Assets (Normalized) | −51.56% | 19.44% | −64.70% |
Return on Equity (Normalized) | −68.44% | 54.76% | −204.18% |
Return on Invested Capital (Normalized) | −67.33% | 35.76% | −65.35% |
Return on Assets
CRDL
TGTX
ARQT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Nbfcvpdj | Gwdc | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Bdrmqhgv | Qrhqnt | $69.1 Bil | |
HLN
| Haleon PLC ADR | Vjqyydrf | Kgs | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Glyzxlpc | Trqs | $15.7 Bil | |
VTRS
| Viatris Inc | Brpqddby | Qqfk | $13.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Ftblpfw | Qgn | $12.4 Bil | |
CTLT
| Catalent Inc | Ngvdmttp | Mtzbdz | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Xcxcsxpqb | Gdf | $4.5 Bil | |
CURLF
| Curaleaf Holdings Inc | Rgkzjkp | Czqdk | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Slpnvrkk | Hbxpfc | $3.5 Bil |